Use of radionuclides in metastatic prostate cancer:pain relief and beyond


Autoria(s): Vengalil, Salil; O'Sullivan, Joe M; Parker, Christopher C
Data(s)

2012

Resumo

Bone metastases in prostate cancer are often the cause of significant morbidity in patients with castrate-resistant disease, and several studies have shown significant pain palliation with systemic radionuclide treatment. The purpose of this review is to discuss the place of radionuclides in the dynamic treatment landscape of metastatic prostate cancer in light of new evidence demonstrating benefit beyond palliation.

Identificador

http://pure.qub.ac.uk/portal/en/publications/use-of-radionuclides-in-metastatic-prostate-cancer(de8e49f4-270f-4c72-a6ad-34825106a9ae).html

http://dx.doi.org/10.1097/SPC.0b013e328355e082

Idioma(s)

eng

Direitos

info:eu-repo/semantics/restrictedAccess

Fonte

Vengalil , S , O'Sullivan , J M & Parker , C C 2012 , ' Use of radionuclides in metastatic prostate cancer : pain relief and beyond ' Current opinion in supportive and palliative care , vol 6 , no. 3 , pp. 310-5 . DOI: 10.1097/SPC.0b013e328355e082

Tipo

article